The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth

@article{Divisov2006TheGH,
  title={The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth},
  author={Jana Divisov{\'a} and Isere Kuiatse and Zawaunyka W Lazard and Heidi Weiss and Franzanne Vreeland and Darryl L Hadsell and Rachel Schiff and Charles Osborne and Adrian V. Lee},
  journal={Breast Cancer Research and Treatment},
  year={2006},
  volume={98},
  pages={315-327}
}
Mammary gland development is dependent upon the growth hormone (GH)/insulin-like growth factor-I (IGF-I) axis, this same axis has also been implicated in breast cancer progression. In this study we investigated the effect of a GH antagonist, pegvisomant (Somavert®, Pfizer), on normal mammary gland development and breast cancer xenograft growth. Intraperitoneal administration of pegvisomant resulted in a 60% suppression of hepatic IGF-I mRNA levels and upto a 70–80% reduction of serum IGF-I… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 40 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 50 references

Insulin, insulin-like growth factors and neoplasia.

Best practice & research. Clinical endocrinology & metabolism • 2008
View 2 Excerpts

Similar Papers

Loading similar papers…